Shalby Ltd (SHALBY) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a consolidated revenue growth of 5.5% YoY, driven by strong performance in the Medtech business, although the hospital segment experienced some softness.
- Consolidated EBITDA margin improved to 15.9% from 14.5% in the same quarter last year, reflecting better operational efficiency and a significant turnaround in the Medtech segment's profitability.
- The Shalby Medtech division was a standout performer, with a remarkable 42.1% YoY revenue growth and a substantial EBITDA improvement, turning a loss in the previous year into a profit.
- The hospital business faced headwinds, including a decline in patient footfall due to heavy monsoons, ongoing TPA (Third-Party Administrator) renegotiations, and a lower incidence of seasonal diseases compared to the previous year.
- Strategic initiatives are underway to revitalize the Shalby International Hospital in Delhi NCR, including rebranding, leadership changes, and onboarding new clinical talent, with a goal to achieve positive EBITDA within the next year.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.